Hologic, Inc. HOLX
General analysis — not personal advice.
Post-take-private there is no public equity to trade; for former shareholders the remaining value driver is the CVR and its revenue conditions.
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Market sentiment
Social sentiment is mostly neutral to slightly positive: attention centers on the cash payout, uncertainty around the CVR earn-out, and reduced transparency post-delisting.
Why this signal
Post-take-private there is no public equity to trade; for former shareholders the remaining value driver is the CVR and its revenue conditions. The appropriate stance is therefore NEUTRAL (monitor) rather than buy/sell, focusing on the likelihood of Breast Health meeting FY2026–FY2027 targets.
Monitor/evaluate CVR exposure (if applicable) and track any updates on Breast Health revenue performance; no public share position can be initiated after delisting.
Recent News
On April 7, 2026, Hologic completed its acquisition by private equity firms Blackstone and TPG in a transaction valued at up to $79 per share. As a result of the deal, the company was taken private and its common stock was delisted from the NASDAQ. In connection with the closing, José (Joe) E. Almeida was appointed as Chief Executive Officer.
Dilution Risk
Assessment: Low
What Firelda Watch includes for Hologic, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more